Select Medical Holdings Exits with $16.50 Cash Payout as Insider Exodus Fuels Investor Fervor

Merger‑Mediated Liquidation: Scully Thomas’ Final Share Sale

On June 30, 2026, Scully Thomas sold his remaining 103,424 shares of Select Medical Holdings Corp. for the merger consideration of $16.50 per share—exactly the price that became the cash payout for every outstanding share once the merger with Stallion Intermediate Corporation and Stallion MergerSub Corp. was consummated. The transaction is a direct consequence of the July 1 takeover, in which a consortium led by Robert Ortenzio and Martin Jackson acquired a controlling stake in the company. Thomas, a long‑time owner, has now exited completely, reflecting the broader consolidation wave sweeping the health‑care services sector.

Insider Exodus and Market Sentiment

The sale was not an isolated event. Within hours of the merger filing, a flurry of insider transactions swept the boardroom: senior executives, including two vice‑chairmen, a chief executive, and several vice presidents, all sold substantial blocks of shares—some up to 7 million—while others bought or sold in smaller amounts. The cumulative effect is a sharp reduction in insider holdings, underscoring the consortium’s confidence that the merger will unlock value. Market sentiment, as gauged on social‑media platforms, remains overwhelmingly positive (+91) with an unusually high buzz of 964 %—a signal that investors and analysts are paying close attention to the transition.

Implications for Investors

For shareholders who have remained, the merger delivers a clear exit strategy: a $16.50 cash payout per share, slightly below the recent close of $16.51 but still above the 52‑week low of $11.65. The deal’s valuation—market cap of $2.13 B and a P/E of 19.1—suggests that the consortium believes the company’s current operations are undervalued relative to its earnings potential. Investors who prefer ongoing exposure to the rehabilitation services market may choose to retain their positions in the new entity, which will continue to operate under the familiar Select Medical brand while benefiting from the consortium’s strategic resources. Conversely, those looking for liquidity and a guaranteed return may consider selling now, given the limited upside once the merger closes and the stock will no longer trade on the NYSE.

Future Outlook for Select Medical Holdings

The consortium’s acquisition marks a turning point for Select Medical. With the merger finalized, the company will operate under a new corporate structure that may streamline its operations, reduce redundancies, and open avenues for expansion into new care settings. The presence of seasoned executives—Ortenzio as chair and Jackson as vice chair—signals a blend of industry expertise and aggressive growth ambition. For investors, the key will be to monitor how the consortium integrates Select Medical’s assets, manages its debt load, and executes any announced expansion plans. In the short term, the market is likely to react to post‑merger performance reports and the consortium’s strategic priorities.

Bottom Line

Scully Thomas’ sale is the last chapter in a high‑profile merger that will reshape the health‑care services landscape. Insider activity points to a collective belief in the transaction’s value, while market sentiment indicates robust interest and a willingness to reassess valuations. For investors, the decision hinges on whether they seek the certainty of a cash payout or the potential upside of a newly positioned, consortium‑backed Select Medical operating under fresh leadership.